FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Библиотека стаков

GH Pulse

Growthintermediate
8
Share
Пептиды

2

Среднедневная дозировка мкг

0

Уровень

intermediate

Добавлено

May 7, 2026

Обзор

GH Pulse is an intermediate-level growth hormone optimization stack that combines two complementary peptides to restore youthful pulsatile GH secretion patterns. This clean, well-studied pairing is the gold standard introduction to serious GH peptide therapy, offering meaningful anabolic and recovery benefits without the complexity of advanced multi-compound protocols. Ipamorelin at 200mcg twice daily is a highly selective growth hormone secretagogue peptide (GHSP) that triggers acute GH release by binding ghrelin receptors (GHS-R) on pituitary somatotrophs. What distinguishes Ipamorelin from other secretagogues like GHRP-6 or GHRP-2 is its remarkable selectivity—it stimulates GH release without significantly elevating cortisol, prolactin, or appetite. This makes it the cleanest pulse trigger available. Twice-daily dosing creates a morning and evening GH spike that mimics the natural diurnal pattern seen in healthy young adults. CJC-1295 (no DAC) at 100mcg twice daily—also known as Modified GRF(1-29)—is a growth hormone releasing hormone analogue with a short half-life of approximately 30 minutes. Unlike the DAC version, this form creates acute GHRH signaling that amplifies each Ipamorelin-triggered pulse without creating sustained baseline elevation. The combination is synergistic: CJC-1295 primes the pituitary by providing the GHRH signal, while Ipamorelin simultaneously pulls the trigger via the ghrelin pathway. Research demonstrates that dual-pathway stimulation produces significantly greater GH output than either peptide alone. Protocol Notes: Both peptides should be administered together subcutaneously on an empty stomach—ideally upon waking (before breakfast) and before bed (at least 2 hours after last meal). Insulin and carbohydrates blunt GH release, so fasting windows around dosing are essential. This stack is well-suited for individuals seeking improved body composition, faster recovery from training, better sleep quality, and the general anti-aging benefits of optimized GH levels. It works particularly well for active adults over 30 noticing slower recovery. Standard cycles run 8-12 weeks, and users typically notice improved sleep quality and recovery within the first two weeks, with body composition changes becoming apparent by week 4-6.

Протокол дозирования

Ipamorelin

Twice per day· subcutaneous

Читать больше о Ipamorelin →

200mcg

на дозу

CJC-1295 (no DAC)

Twice per day· subcutaneous

Читать больше о CJC-1295 (no DAC) →

100mcg

на дозу

Цели и доказательства

Уровень доказательств:community

Comments

Sign in to join the discussion

Уведомление: Этот стак представлен сообществом и предназначен для исследовательских целей только. Peptide Contacts не проверяет безопасность или эффективность представленных стаков. Всегда проконсультируйтесь с квалифицированным медицинским специалистом перед использованием любого протокола пептидов.